Australian earnings preview – CSL

CSL Limited (CSL) is Australia’s largest drug maker, one of the world’s largest biotech companies, and a leader in flu treatments and plasma protein therapies. It reports its half-year numbers on the 18th of February.

Australia

CSL is renowned as a quality company, however, unlike the broader market, its share price is trading about 20% below its 2020 high of $342.75. The source of this underperformance is a sequence of negative developments and a lack of positive catalysts to help the share price recover lost ground.

Learn how to trade shares here

CSL’s plasma collection operations have been hampered by Covid-19 restrictions, limiting its ability to collect plasma. Plasma is an essential ingredient in some of CSL’s immunoglobulin therapies which account for almost half of CSL’s sales. The company is continuing to work on ways to mitigate this issue.

The Covid-19 vaccine CSL was working on with the University of Queensland was scrapped in December after it delivered misleading results regarding HIV diagnoses in trials. Despite signing contracts to produce other vaccines including 51 million doses of AstraZeneca’s vaccine, CSL does not expect the production of vaccines to see a material lift in revenues.

Finally, the company is faced by the headwind of a rising AUD/USD, as a significant portion of its revenues are earned offshore in US dollars.

At its Annual General Meeting in December, CSL said it expects NPAT to grow at between US$2.17 billion to $2.265 billion implying growth of between 3% and 8%. Not overly exciting for a company trading on a price/earnings ratio of more than 40.

Technically, the decline from the $342.75 high of February 2020 appears to be countertrend after a stunning multi-year rally. Once the correction is complete, the uptrend is expected to resume.

As such, we would consider buying a dip into support offered by the trend channel and the March low, $250/240 area. Keeping in mind, a sustained break above trend channel resistance $315 area, would be confirmation the uptrend has resumed.  

Australian earnings preview – CSL

Source Tradingview. The figures stated areas of the 5th of February 2021. Past performance is not a reliable indicator of future performance.  This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.